.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Healthtrust
Baxter
Cantor Fitzgerald
US Department of Justice
Covington
McKinsey
Citi
Fish and Richardson
Harvard Business School

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,703,403

« Back to Dashboard

Which drugs does patent 6,703,403 protect, and when does it expire?


Patent 6,703,403 protects KALETRA, NORVIR, PREZISTA, and TECHNIVIE, and is included in nine NDAs. There have been zero Paragraph IV challenges on Kaletra, Norvir, and .

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-three patent family members in fourteen countries.

Summary for Patent: 6,703,403

Title: Method for improving pharmacokinetics
Abstract:A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
Inventor(s): Norbeck; Daniel W. (Crystal Lake, IL), Kempf; Dale J. (Libertyville, IL), Leonard; John M. (Lake Bluff, IL), Bertz; Richard J. (Kenosha, WI)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/957,171
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AbbvieKALETRAlopinavir; ritonavirCAPSULE;ORAL021226-001Sep 15, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe
AbbvieNORVIRritonavirCAPSULE;ORAL020945-001Jun 29, 1999RXYesYes► Subscribe► Subscribe► Subscribe
AbbvieKALETRAlopinavir; ritonavirSOLUTION;ORAL021251-001Sep 15, 2000AARXYesYes► Subscribe► Subscribe► Subscribe
AbbvieNORVIRritonavirSOLUTION;ORAL020659-001Mar 1, 1996RXYesYes► Subscribe► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateSUSPENSION;ORAL202895-001Dec 16, 2011RXYesYes► Subscribe► Subscribe► Subscribe
AbbvieKALETRAlopinavir; ritonavirTABLET;ORAL021906-002Nov 9, 2007RXYesNo► Subscribe► Subscribe► Subscribe
AbbvieKALETRAlopinavir; ritonavirTABLET;ORAL021906-001Oct 28, 2005RXYesYes► Subscribe► Subscribe► Subscribe
AbbvieNORVIRritonavirTABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-004Dec 18, 2008RXYesNo► Subscribe► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-005Dec 18, 2008RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,703,403

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,037,157 Method for improving pharmacokinetics► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,703,403

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany69637511► Subscribe
Germany69637976► Subscribe
Denmark0871465► Subscribe
Denmark1284140► Subscribe
Denmark1293207► Subscribe
Denmark2295052► Subscribe
European Patent Office0871465► Subscribe
European Patent Office1210941► Subscribe
European Patent Office1273298► Subscribe
European Patent Office1293207► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
Cerilliant
Mallinckrodt
Accenture
Teva
Dow
Baxter
Deloitte
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot